CMPI
Checkmate Pharmaceuticals, Inc. [CMPI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CMPI Stock Summary
In the News
CMPI Financial details
Company Rating
-
Market Cap
0
Income
-63.16M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
30
Optionable
No
Shortable
Yes
Earnings
12 May 2022
P/E
-1.63
Forward P/E
-
PEG
0.67
P/S
-
P/B
1.45
P/C
-
P/FCF
-
Quick Ratio
5.4
Current Ratio
7.89
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.92
EPS next Y
-
EPS next Q
-
EPS this Y
66.32%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
17.74%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-78%
ROE
-63%
ROC
-0.88%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
10.49-10.5
52W High
+5%
52W Low
+5%
RSI
-
Rel Volume
0.27
Avg Volume
233.02K
Volume
63.65K
Perf Week
0%
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
0%
Price
10.5
Change
-
Company Profile
- Volume Average 233.02K
- Employee 30
- CEO Mr. Barry A. Labinger
- Headquarters Cambridge,MA,US
- IPO Date 2020-08-07
-
Website
https://www.checkmatepharma.com 
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
